Canertinib

Canertinib is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR, HER-2 and ErbB-4. By 2015, Pfizer had discontinued development of the drug.
Canertinib has been reported as a substrate for the transporter protein OATP1B3. Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions. Canertinib is not an inhibitor of the OATP1B1 or OATP1B3 transporters.